BioCentury | Dec 16, 2016
Company News

SOM Biotech deal

...SOM said that in November it granted an undisclosed company worldwide rights to tolcapone (SOM0226). The...
...amyloidosis. SOM declined to disclose additional details. SOM Biotech S.L. , Barcelona, Spain Business: Endocrine/Metabolic Alicia Parker SOM0226 Tolcapone SOM...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Neurology

...CNS. Next steps include further optimization of the compounds. Roche markets the COMT inhibitor Tasmar tolcapone...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: Catechol-O-methyl-transferase (COMT)

...that inhibited the activity of human COMT with greater potency than the COMT inhibitors Tasmar tolcapone...
BioCentury | Dec 7, 2015
Regulation

Action in amyloidosis

...antisense inhibitor Ph II/III for FAP mNIS+7 and Norfolk QOL questionnaire SOM Biotech S.L. Tolcapone (SOM0226...
BioCentury | Nov 9, 2015
Clinical News

Tolcapone: Phase IIa data

...doses of 200 mg oral SOM0226 and up to 3 doses of 100 mg oral SOM0226...
...Hereditary ATTR amyloidosis meeting in Paris. SOM Biotech S.L. , Barcelona, Spain Product: Tolcapone ( SOM0226...
BioCentury | Nov 4, 2015
Clinical News

Alnylam, SOM Biotech, Isis update TTR programs

...Biotech's SOM0226 tolcapone showed stabilization of plasmatic TTR in all 21 patients receiving the therapy. SOM0226...
...is a stabilizer of tetrameric TTR and a TTR fibril disruptor. Roche (SIX:ROG; OTCQX:RHHBY) markets tolcapone...
BioCentury | Aug 11, 2008
Company News

Meda, Valeant Pharmaceuticals International deal

...the North American market. The deal includes Valeant’s Mestinon pyridostigmine to treat myasthenia gravis; Tasmar tolcapone...
BioCentury | Aug 5, 2008
Company News

Meda acquiring Valeant units in Europe

...is the North American market. The deal includes Mestinon pyridostigmine to treat myasthenia gravis; Tasmar tolcapone...
BioCentury | Jan 22, 2007
Company News

Jazz, Valeant Pharmaceuticals International deal

...Xyrem, which is approved in Canada, to launch mid-year. VRX markets Zelapar selegiline and Tasmar tolcapone...
BioCentury | Apr 18, 2005
Strategy

Reprofiler report card

...female patients with altered activity of the enzyme. Unfortunately, the only marketed COMT inhibitor, Tasmar tolcapone...
Items per page:
1 - 10 of 14